Cassava Sciences Inc (SAVA)

NASDAQ
46.85
+4.98(+11.89%)
  • Volume:
    5,068,709
  • Day's Range:
    40.80 - 47.10
  • 52 wk Range:
    13.84 - 100.00

SAVA Overview

Prev. Close
41.87
Day's Range
40.8-47.1
Revenue
-
Open
40.83
52 wk Range
13.84-100
EPS
-1.52
Volume
5,068,709
Market Cap
1.84B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,298,935
P/E Ratio
-13.47
Beta
0.695
1-Year Change
-32.4%
Shares Outstanding
40,097,917
Next Earnings Date
Nov 01, 2022
What is your sentiment on Cassava Sciences?
or
Vote to see community's results!

Cassava Sciences Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Cassava Sciences Inc Analysis

Cassava Sciences Inc Company Profile

Cassava Sciences Inc Company Profile

Employees
11

Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.

Read More

Analyst Price Target

Average72.50 (+54.75% Upside)
High124
Low8
Price46.85
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • I told you its go to 100 soon
    0
    • Not stopping at 100
      0
    • Bob SandersBuy 45 sell 100
      0
    • Abdullah ShahnewazDon't think will go 100 sell if you are green
      0
  • This should be 15. Doesn’t generate revenue. third phase clinical trial ends Oct 2023 at least. Drug performance is speculative,lots of negative stuff
    10
    • 100 soon
      0
      • why?
        0
      • Why??
        0
      • When?
        0
    • what to expect for tomorrow?
      0
      • push this to 40
        0
        • Advise to buy more even with current price ??!!
          0
          • Last time it was gone 5-100 in 3 days
            0
          • Vicky Chopraohhhh my God !!
            0
        • 100 soon again
          0
          • Is the SEC actively investigating the short and distort against cassava sciences?
            0
            • Any reasons for this drop?
              0
              • Some irregularities on the drug. NY times is saying.
                0
            • bio junk is like gambling - thankfully I do not
              1